Recruiting

Nicotinamide Mononucleotide for Immunosenescence in Middle-aged and Elderly with Metabolic Disorders

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

NMN

+ Placebo

Dietary Supplement
Who is being recruted

From 50 to 70 Years
+18 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Other Study

Placebo-Controlled
Interventional
Study Start: June 2025
See protocol details

Summary

Principal SponsorQing Su
Study ContactSu
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: June 5, 2025

Actual date on which the first participant was enrolled.

This study is exploring the effects of a supplement called Nicotinamide Mononucleotide (NMN) on the immune system and metabolism of older adults. Specifically, it targets those aged 50 to 70 who have metabolic disorders, aiming to see if this supplement can improve immune function and metabolic health. The importance of this study lies in its potential to enhance the quality of life for middle-aged and elderly individuals by addressing age-related declines in immunity and metabolic function. Participants in the study will take one NMN sustained-release tablet or a placebo daily before breakfast for 26 weeks. The researchers will monitor participants through visits at months 1, 3, and 6. The main focus is on measuring specific immune cells in the blood to see the impact of NMN. Additionally, the study will look at secondary factors such as liver fat, body composition, blood sugar levels, and overall fitness. Safety will be evaluated by checking routine blood and urine tests, and assessing liver and kidney function.

Official TitleThe Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
NCT06907329
Principal SponsorQing Su
Study ContactSu
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

126 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Other Study

Some studies explore topics that don't fall into a specific category. These might include innovative research, new technologies, or emerging healthcare areas.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 50 to 70 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

3 inclusion criteria required to participate
Age 50-70 years with overweight or obesity (BMI 24kg/m2);
At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c <7% without glucose-lowering drug therapy;
Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.
15 exclusion criteria prevent from participating
Patients with tumours;
Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
Severe cardiovascular disease or cardiac insufficiency;
Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg;
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
NMN tablets (1000mg/tablet) , 1 tablet daily before breakfast

Group II

Placebo
Matching Placebo (tablets) once daily before breakfast

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, ChinaOpen Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine in Google Maps
Recruiting
One Study Center